机器学习优化抗生素组合:美罗培南与多黏菌素B针对碳青霉烯耐药鲍曼不动杆菌的给药策略
本研究在体外中空纤维感染模型中评估美罗培南与多黏菌素B(PMB)组合对碳青霉烯耐药鲍曼不动杆菌的杀菌效果,并利用机制性药效模型和遗传算法优化给药方案。单药治疗24小时出现再生长,高暴露PMB组合可实现完全根除;遗传算法预测优化方案为美罗培南19.6 g/天延长输注2小时每5小时一次联合PMB 5.17 mg/kg/天延长输注2小时每6小时一次,并建议负荷剂量。
要点
- 单药治疗24小时再生长至约10^10 cfu/mL,高暴露PMB组合可实现完全根除。
- 机制模型显示PMB敏感亚群SC50为0.0927 mg/L,耐药亚群为3.40 mg/L。
- 遗传算法偏好延长输注和缩短给药间隔以提高%T>MIC。
核心结论
- 利用体外数据、药效模型和群体药代动力学可优化组合给药方案,超越传统药效指标。
研究设计与样本
- 体外中空纤维感染模型,初始接种量10^8 cfu/mL,观察14天。
- 菌株为鲍曼不动杆菌N16870,美罗培南MIC=16 mg/L,PMB MIC=0.5 mg/L。
- 基于机制性药效模型和群体药代动力学开发遗传算法优化给药参数。
主要发现
- 单药治疗24小时再生长至约10^10 cfu/mL。
- 高暴露PMB组合方案在336小时达到完全根除(0 cfu/mL)。
- 机制模型显示PMB敏感亚群SC50为0.0927 mg/L,耐药亚群为3.40 mg/L。
- 遗传算法预测使90%模拟对象从10^8 cfu/mL降至100 cfu/mL需美罗培南19.6 g/天2hPI q5h联合PMB 5.17 mg/kg/天2hPI q6h。
- 建议0小时美罗培南和PMB负荷剂量分别为日剂量的80.5%和42.2%。
关键数值与推荐
- 遗传算法预测方案:美罗培南19.6 g/天延长输注2小时每5小时一次联合PMB 5.17 mg/kg/天延长输注2小时每6小时一次。
- 负荷剂量:美罗培南80.5%日剂量,PMB 42.2%日剂量。
- 目标:90%模拟对象从10^8 cfu/mL降至100 cfu/mL。
临床怎么用
- 提示临床可考虑延长美罗培南输注时间并缩短给药间隔以提高%T>MIC。
- 高暴露PMB联合美罗培南可能实现完全根除,但需进一步临床验证。
局限性
- 研究为体外模型和模拟预测,未在临床患者中验证。
- 仅测试单一菌株,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Increased rates of carbapenem-resistant strains of Acinetobacter baumannii have forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical, unoptimized combination therapy. Therefore, the objectives of this study were: (a) to evaluate the in vitro pharmacodynamics of meropenem and polymyxin B (PMB) combinations against A. baumannii; (b) to utilize a mechanism-based mathematical model to quantify bacterial killing; and (c) to develop a genetic algorithm (GA) to define optimal dosing strategies for meropenem and PMB. METHODS: A. baumannii (N16870; MICmeropenem = 16 mg/L, MICPMB = 0.5 mg/L) was studied in the hollow-fibre infection model (initial inoculum 108 cfu/mL) over 14 days against meropenem and PMB combinations. A mechanism-based model of the data and population pharmacokinetics of each drug were used to develop a GA to define the optimal regimen parameters. RESULTS: Monotherapies resulted in regrowth to ~1010 cfu/mL by 24 h, while combination regimens employing high-intensity PMB exposure achieved complete bacterial eradication (0 cfu/mL) by 336 h. The mechanism-based model demonstrated an SC50 (PMB concentration for 50% of maximum synergy on meropenem killing) of 0.0927 mg/L for PMB-susceptible subpopulations versus 3.40 mg/L for PMB-resistant subpopulations. The GA had a preference for meropenem regimens that improved the %T > MIC via longer infusion times and shorter dosing intervals. The GA predicted that treating 90% of simulated subjects harbouring a 108 cfu/mL starting inoculum to a point of 100 cfu/mL would require a regimen of meropenem 19.6 g/day 2 h prolonged infusion (2 hPI) q5h + PMB 5.17 mg/kg/day 2 hPI q6h (where the 0 h meropenem and PMB doses should be 'loaded' with 80.5% and 42.2% of the daily dose, respectively). CONCLUSION: This study provides a methodology leveraging in vitro experimental data, a mathematical pharmacodynamic model, and population pharmacokinetics provide a possible avenue to optimize treatment regimens beyond the use of the 'traditional' indices of antibiotic action.
引用
- Smith NM, Lenhard JR, Boissonneault KR, et al. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2020. PMID: 32061797. doi:10.1016/j.cmi.2020.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。